Related Experiment Videos
Juvenile rheumatoid arthritis
1Childrens Hospital Los Angeles, University of Southern California School of Medicine, 90027, USA.
Insights
Recent research defines juvenile rheumatoid arthritis (JRA) heterogeneity, linking cytokine profiles to disease subtypes and identifying therapeutic advances. Key findings include etanercept efficacy and methotrexate
Area of Science:
- Rheumatology
- Immunology
- Pediatrics
Background:
- Juvenile rheumatoid arthritis (JRA) is a heterogeneous autoimmune disease.
- Understanding its varied pathogenesis and treatment responses is crucial for pediatric rheumatology.
Purpose of the Study:
- To synthesize recent scientific publications defining JRA heterogeneity.
- To highlight advancements in understanding JRA pathogenesis and treatment.
Main Methods:
- Review of scientific literature published within the past year concerning JRA.
- Analysis of findings related to cytokine profiles, disease activity, and therapeutic interventions.
Main Results:
- Systemic JRA associated with decreased IL-10 and soluble IL-6 receptor.
- IL-4 may play an anti-inflammatory role in pauciarticular JRA.
- Lower platelet activating factor acetylhydrolase in active JRA linked to atherogenesis risk.
- Etanercept Phase 3 trial confirmed efficacy and safety.
- Intra-articular steroids and methotrexate show efficacy.
- Methotrexate hepatotoxicity risk factors identified.
- Osteoclasts implicated in joint erosions.
- Cyclosporine A, mycophenolate mofetil, and methotrexate effective for refractory uveitis.
Conclusions:
- Recent publications significantly advance the understanding of JRA heterogeneity.
- New insights into JRA pathogenesis and effective treatment strategies have emerged.
- Continued research is vital for improving outcomes in pediatric rheumatic diseases.
Abstract:
The heterogeneous nature of juvenile rheumatoid arthritis is further defined in publications from the past year. Decreased IL-10 production, an anti-inflammatory cytokine, and soluble IL-6 receptor are associated with systemic juvenile rheumatoid arthritis (JRA). IL-4 may have an anti-inflammatory role in the pathogenesis of pauciarticular JRA and may protect, along with IL-10, against the development of joint erosions. Active JRA is associated with lower levels of platelet activating factor acetylhydrolase, which may contribute to the loss of anti-inflammatory activity and increased risk of atherogenesis. The phase 3 clinical trial of etanercept confirmed its efficacy and safety in JRA. Intra-articular steroids are safe and effective in the treatment of JRA. Methotrexate does have disease-modifying effects. The risk of hepatotoxicity with methotrexate use increases with serial transaminase abnormalities and with obesity. Osteoclasts are responsible for joint erosions. Cyclosporine A, mycophenolate mofetil, and methotrexate are effective in the treatment of refractory uveitis. During the past year a number of scientific publications have contributed significantly to our understanding and treatment of juvenile rheumatoid arthritis.